HIPE
The HIPE RCT - Comparison Between Transarterial Musculoskeletal Embolization (TAME) and Platelet-Rich Plasma (PRP) Injection for the Treatment of Greater Trochanteric Pain Syndrome - A Randomized Controlled Trial
Sponsor study identifier
interventional
30
1 country
1
Study Start
January 5, 2026
Actual (reported)Primary Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Greater Trochanteric Pain Syndrome (GTPS) is a common cause of lateral hip pain that can significantly affect daily activities and quality of life. Standard treatments include physical therapy, anti-inflammatory medications, and local injections, but many patients continue to experience persistent symptoms. This randomized controlled trial aims to compare two minimally invasive treatment options for GTPS: transarterial musculoskeletal embolization (TAME) and platelet-rich plasma (PRP) injection. Participants will be randomly assigned to receive either TAME or PRP. The main goal of the study is to evaluate which treatment is more effective in reducing pain. Secondary goals include comparing functional improvement, quality of life, and safety between the two treatments. Pain and functional outcomes will be assessed at baseline and during follow-up at 1, 3, 6, and 12 months after treatment. This study seeks to provide evidence on the effectiveness and safety of TAME compared with PRP injection for patients with Greater Trochanteric Pain Syndrome.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 5, 2026
Actual (reported)February 1, 2026
Actual (reported)February 9, 2026
Actual (reported)December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Pain reduction assessed by Visual Analog Scale (VAS)
Change in pain intensity from baseline measured using the Visual Analog Scale (VAS), comparing participants treated with transarterial musculoskeletal embolization (TAME) versus platelet-rich plasma (PRP) injection.
Baseline, 1 month, 3 months, 6 months, and 12 months after treatment
Functional improvement assessed by WOMAC score
Baseline, 1 month, 3 months, 6 months, and 12 months after treatment
Quality of life assessed by EQ-5D-5L questionnaire
Baseline, 1 month, 3 months, 6 months, and 12 months after treatment
Incidence of adverse events related to TAME or PRP
From treatment to 12 months after the procedure
Participants assigned to this arm will undergo transarterial musculoskeletal embolization (TAME) under local anesthesia. The procedure will be performed by an experienced interventional radiologist using selective catheterization of pathological peri-trochanteric vessels supplying the affected hip structures. Embolization will be carried out using a temporary, reabsorbable embolic microsphere (Nexsphere-F®, CE approved) to achieve transient vessel occlusion. The aim of the procedure is to reduce pathological neovascularization and inflammation associated with Greater Trochanteric Pain Syndrome.
Participants assigned to this arm will receive a single ultrasound-guided intratendinous injection of autologous platelet-rich plasma (PRP) into the affected gluteal tendon. The procedure will be performed by an orthopedic hip specialist under sterile conditions. PRP will be prepared from the participant's own blood using a standardized centrifugation protocol. The objective of this intervention is to promote tendon healing and reduce pain and functional impairment associated with Greater Trochanteric Pain Syndrome.
Transarterial musculoskeletal embolization (TAME) is performed under local anesthesia by an experienced interventional radiologist. The procedure consists of selective catheterization and embolization of pathological peri-trochanteric vessels supplying the affected hip structures. A temporary, reabsorbable embolic microsphere (Nexsphere-F®, CE approved) is used to achieve transient vessel occlusion, with the objective of reducing pathological neovascularization and inflammation associated with Greater Trochanteric Pain Syndrome.
Unidade Local de Saúde do Alto Ave
Guimarães, Portugal
Pedro M M Lopes, MD
Unidade Local de Saúde do Alto Ave
First Submitted
February 1, 2026
First Posted
February 9, 2026
Study Start
January 5, 2026
Actual (reported)Primary Completion
December 31, 2027
EstimatedA Randomized Controlled Trial of Ultrasound-guided Platelet-Rich-Plasma (PRP) Injection Versus Extracorporeal Shock Wave Therapy (ESWT) for Great Trochanter Pain Syndrome (GTPS) With Gluteus Medius or Minimus Tendinopathy
Platelet-rich plasma (PRP) injection consists of a single ultrasound-guided intratendinous administration of autologous PRP into the affected gluteal tendon. PRP is prepared from the participant's own blood using a standardized centrifugation protocol and injected under sterile conditions by an orthopedic hip specialist. The intervention aims to promote tendon healing and reduce pain and functional impairment associated with Greater Trochanteric Pain Syndrome.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 9, 2026
Record last verified: 2025-09
De-identified individual participant data (IPD) underlying the results of this study, including baseline characteristics and outcome measures (VAS, WOMAC, EQ-5D-5L, and adverse events), will be made available for secondary research purposes.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: